title: Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries.
abstract: OBJECTIVE
  We assessed the use and effects of acute intravenous and later oral atenolol treatment in a prospectively planned post hoc analysis of the GUSTO-I dataset.
  
  
  BACKGROUND
  Early intravenous beta blockade is generally recommended after myocardial infarction, especially for patients with tachycardia and/or hypertension and those without heart failure.
  
  
  METHODS
  Besides one of four thrombolytic strategies, patients without hypotension, bradycardia or signs of heart failure were to receive atenolol 5 mg intravenously as soon as possible, another 5 mg intravenously 10 min later and 50 to 100 mg orally daily during hospitalization. We compared the 30-day mortality of patients given no atenolol (n=10,073), any atenolol (n=30,771), any intravenous atenolol (n=18,200), only oral atenolol (n=12,545) and both intravenous and oral drug (n=16,406), after controlling for baseline differences and for early deaths (before oral atenolol could be given).
  
  
  RESULTS
  Patients given any atenolol had a lower baseline risk than those not given atenolol. Adjusted 30-day mortality was significantly lower in atenolol-treated patients, but patients treated with intravenous and oral atenolol treatment vs. oral treatment alone were more likely to die (odds ratio, 1.3; 95% confidence interval, 1.0 to 1.5; p=0.02). Subgroups had similar rates of stroke, intracranial hemorrhage and reinfarction, but intravenous atenolol use was associated with more heart failure, shock, recurrent ischemia and pacemaker use than oral atenolol use.
  
  
  CONCLUSIONS
  Although atenolol appears to improve outcomes after thrombolysis for myocardial infarction, early intravenous atenolol seems of limited value. The best approach for most patients may be to begin oral atenolol once stable.
authors.affiliation: Division of Cardiology, University Hospital Basel, Switzerland.
authors.forename: M
authors.initials: M
authors.lastname: Pfisterer
authors.forename: J L
authors.initials: JL
authors.lastname: Cox
authors.forename: C B
authors.initials: CB
authors.lastname: Granger
authors.forename: S J
authors.initials: SJ
authors.lastname: Brener
authors.forename: C D
authors.initials: CD
authors.lastname: Naylor
authors.forename: R M
authors.initials: RM
authors.lastname: Califf
authors.forename: F
authors.initials: F
authors.lastname: van de Werf
authors.forename: A L
authors.initials: AL
authors.lastname: Stebbins
authors.forename: K L
authors.initials: KL
authors.lastname: Lee
authors.forename: E J
authors.initials: EJ
authors.lastname: Topol
authors.forename: P W
authors.initials: PW
authors.lastname: Armstrong
mesh_terms: D000284:Administration, Oral; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D000368:Aged; D001262:Atenolol / Q000008:administration & dosage* / Q000009:adverse effects; D002423:Cause of Death; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality; D012306:Risk; D013300:Streptokinase / Q000008:administration & dosage* / Q000009:adverse effects; D015996:Survival Rate; D015912:Thrombolytic Therapy; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists; D001262:Atenolol; D013300:Streptokinase